Tag Archives: Yaron Werber

Cowen & Co. Reaffirms Their Buy Rating on Alector (ALEC)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Alector (ALEC – Research Report). The company’s shares closed last Monday at $19.76. According to TipRanks.com, Werber is a 5-star analyst with an average

Cowen & Co. Sticks to Its Buy Rating for Bluebird Bio (BLUE)

In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Bluebird Bio (BLUE – Research Report). The company’s shares closed last Monday at $79.42, close to its 52-week low of $71.42. According to TipRanks.com,

Cowen & Co. Keeps Their Buy Rating on Orchard Therapeutics (ORTX)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Orchard Therapeutics (ORTX – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $11.39. According to TipRanks.com, Werber is a 5-star

Cowen & Co. Remains a Buy on Bluebird Bio (BLUE)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Bluebird Bio (BLUE – Research Report). The company’s shares closed last Monday at $73.68, close to its 52-week low of $72.02. According to TipRanks.com,

Cowen & Co. Sticks to Their Buy Rating for Dicerna Pharma (DRNA)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Dicerna Pharma (DRNA – Research Report). The company’s shares closed last Monday at $21.39, close to its 52-week high of $23.57. According to TipRanks.com,

Cowen & Co. Remains a Buy on Rocket Pharmaceuticals (RCKT)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday. The company’s shares closed last Monday at $14.55. According to TipRanks.com, Werber is a 5-star analyst with an average return of 10.4%